Pediatric applications of Dotatate: early diagnostic and therapeutic experience
| Autor: | Victor J. Seghers, Kevin M. McElroy, Larry A. Binkovitz, Andrew T. Trout, Michael Czachowski, Lisa J. States, Aida N. Lteif |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.diagnostic_test Somatostatin receptor business.industry medicine.medical_treatment Neuroendocrine tumors medicine.disease 030218 nuclear medicine & medical imaging Radiation exposure Radiation therapy 03 medical and health sciences 0302 clinical medicine Positron emission tomography Neuroblastoma Pediatrics Perinatology and Child Health medicine Medical imaging Radiology Nuclear Medicine and imaging Radiology business 030217 neurology & neurosurgery |
| Zdroj: | Pediatric Radiology. 50:882-897 |
| ISSN: | 1432-1998 0301-0449 |
| DOI: | 10.1007/s00247-020-04688-z |
| Popis: | In recent years, new somatostatin receptor agents (SSTRs) have become available for diagnostic imaging and therapy in neuroendocrine tumors. The novel SSTR ligand DOTA-DPhel-Tyr3-octreotate (Dotatate) in particular can be linked with 68Gallium for diagnostic imaging purposes, and with the β-emitter 177Lutetium for radiotherapy in the setting of neuroendocrine tumors. Dotatate imaging offers distinct advantages in the evaluation of neuroendocrine tumors compared to standard techniques, including greater target-to-background ratio and lesion conspicuity, high sensitivity/specificity, improved spatial resolution with positron emission tomography (PET)/CT or PET/MR, and decreased radiation exposure. Although currently off-label in pediatrics, Dotatate theranostics in children are being explored, most notably in the setting of neuroblastoma and hereditary neuroendocrine syndromes. This article provides a multicenter case series of Dotatate imaging and therapy in pediatric patients in order to highlight the spectrum of potential clinical applications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink